Examination of platelet function in whole blood under dynamic flow conditions with the cone and plate(let) analyzer: effect of erythrocytosis and thrombocytosis.
We studied cone and plate(let) analysis (CPA) for evaluating global platelet function in whole blood under arterial flow conditions (approximately 1,800 seconds(-1)). CPA allows direct visualization and quantitation of platelet adhesion (surface coverage [SC]) and determination of average aggregate size (AS) following brief shearing of a small blood sample (3.2% sodium citrate) in plastic wells. By using blood from healthy volunteers manipulated to alter platelet or RBC counts and blood from patients with myeloproliferative disorders (MPDs), quantitative and qualitative changes in SC and AS were observed. Thrombocytosis resulted in increased SC, whereas erythrocytosis increased AS. The RBC volume (mean corpuscular volume) had no effect. It is interesting that differences in CPA AS were discerned among subgroups of patients with MPD undergoing different treatment regimens. These studies suggest that CPA platelet deposition patterns may provide novel insight into global platelet function during hemodynamic flow.
Peerschke
Ellinor I
EI
Department of Pathology and Laboratory Medicine, Weill Medical College of Cornell University, New York, NY 11777, USA.
Silver
Richard T
RT
Weksler
Babette B
BB
Yin
Wei
W
Bernhardt
Bernard
B
Varon
David
D
D001549:Benzamides; D001783:Blood Flow Velocity / Q000502:physiology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D006400:Hematocrit; D006801:Humans; D000068877:Imatinib Mesylate; D010879:Piperazines / Q000627:therapeutic use; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000502:physiology; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010976:Platelet Count; D010979:Platelet Function Tests / Q000295:instrumentation / Q000379:methods; D011086:Polycythemia / Q000097:blood*; D011743:Pyrimidines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D013922:Thrombocytosis / Q000097:blood* / Q000188:drug therapy; D013997:Time Factors
D001549:Benzamides; D010879:Piperazines; D010975:Platelet Aggregation Inhibitors; D011743:Pyrimidines; D011799:Quinazolines; D000068877:Imatinib Mesylate; C021139:anagrelide